Sort   by:  
 Page size 
UnknownRituximab Maintenance for a Maximum of 5 Years After Single-Agent Rituximab Induction in Follicular Lymphoma: Results of the Randomized Controlled Phase III Trial SAKK 35/03.
Not available
S-EPMC4872010 | biostudies-literature
UnknownThe identification of TCF1+ progenitor exhausted T cells in THRLBCL may predict a better response to PD-1/PD-L1 blockade.
Not available
S-EPMC9636403 | biostudies-literature
UnknownEfficacy of 90Y ibritumomab-tiuxetan treatment in a case of resistant gastric MALT non-Hodgkin's lymphoma.
Not available
S-EPMC3234051 | biostudies-literature
UnknownItalian real-life experience with brentuximab vedotin: results of a large observational study of 40 cases of relapsed/refractory systemic anaplastic large cell lymphoma.
Not available
S-EPMC5664397 | biostudies-literature
UnknownGene expression profiling and FDG-PET radiomics uncover radiometabolic signatures associated with outcome in DLBCL.
Not available
S-EPMC9979764 | biostudies-literature
UnknownProlonged rituximab maintenance in follicular lymphoma patients: long-term results of the SAKK 35/03 randomized trial.
Not available
S-EPMC7724909 | biostudies-literature
UnknownImmune Signatures Identify Patient Subsets Deriving Long-Term Benefit From First-Line Rituximab in Follicular Lymphoma.
Not available
S-EPMC11804214 | biostudies-literature
UnknownAnti-CD20 maintenance strategies to face the challenge of COVID-19 pandemic in follicular lymphoma: results from the R-FolSTOP multicentre Italian study.
Not available
S-EPMC12031816 | biostudies-literature
UnknownIELSG30 phase 2 trial: intravenous and intrathecal CNS prophylaxis in primary testicular diffuse large B-cell lymphoma.
Not available
S-EPMC10966164 | biostudies-literature
UnknownSix-month rituximab-lenalidomide regimen in advanced untreated follicular lymphoma: SAKK 35/10 trial 10-year update.
Not available
S-EPMC11999207 | biostudies-literature
Sort   by:  
 Page size